The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price ...

Buying stocks is quick and straightforward once you have a brokerage account. Learn how with this step-by-step guide. Many, or all, of the products featured on this page are from our advertising ...

One of Monte Rosa's main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders.

President’s memo asks agencies for more details on how to adjust U.S. tariffs to reflect the duties imposed by other nations.

India's future is being shaped by a new wave of innovative companies revolutionizing industries through technology, ...